Developing a test to diagnose cancer in fluid around the lungs
Development of a Molecular Assay to Diagnose Malignant Pleural Effusions
This study is testing a new blood test that helps doctors better identify cancer in patients with fluid around their lungs, making it easier to tell if the fluid is caused by cancer or something else.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Precision Epigenomics, INC. NIH-funded |
| Lab location | 1 site (Tucson, UNITED STATES) |
| Project ID | NIH-11005186 on NIH RePORTER |
What this research studies
This research focuses on creating a new molecular diagnostic test called the Sentinel-MPE liquid biopsy assay, which aims to improve the accuracy of diagnosing malignant pleural effusions (MPE). The test can detect over twenty different types of cancer by analyzing fluid samples from around the lungs. Current methods, like cytology, often miss malignant cells, so this new approach seeks to provide a more reliable alternative. The study will involve multiple clinical sites to validate the effectiveness of this assay in distinguishing between malignant and benign conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients who have pleural effusions and are being evaluated for potential malignancies.
Not a fit: Patients with pleural effusions that are already diagnosed as benign or those who do not have any pleural effusions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more accurate and efficient diagnosis of cancer in patients with pleural effusions.
How similar studies have performed: Previous research has shown promise in using liquid biopsy assays for cancer detection, indicating that this approach may be effective.
Where this research is happening
Tucson, UNITED STATES
- Precision Epigenomics, INC. — Tucson, United States (Active)
Researchers
- Principal investigator: Nelson, Mark Anthony — Precision Epigenomics, INC.
- Study coordinator: Nelson, Mark Anthony
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.